Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 0.60 |
| ▸ | CDK1 | P06493 | 1/20 | 0.60 |
| ▸ | CDK4 | P11802 | 1/20 | 0.60 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.60 |
| ▸ | CCND1 | P24385 | 1/20 | 0.60 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.60 |
| ▸ | PKMYT1 | Q99640 | 3/20 | 0.58 |
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | CCNK | O75909 | 1/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.53 |
| ▸ | CCND3 | P30281 | 1/20 | 0.53 |
| ▸ | CDK9 | P50750 | 1/20 | 0.53 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.53 |
| ▸ | WEE1 | P30291 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 2/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12725748 | 0.84 | LRRK2 (0.64) | CDK2CDK1CDK4CCND1CCNE1 | |
| SCHEMBL12671427 | 0.82 | WEE1 (0.58) | CDK2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL23704673 | 0.82 | PKMYT1 (0.69) | CDK2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL27745780 | 0.81 | CDK4 (0.67) | CDK2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL1633570 | 0.79 | CDK2 (0.50) | CDK2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL23704665 | 0.78 | CCNK (0.65) | CDK2PKMYT1SYKCCNKCCNA2 | |
| SCHEMBL13363307 | 0.78 | CDK4 (0.55) | CDK2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL13498288 | 0.78 | CDK2 (0.50) | CDK2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL1634274 | 0.78 | CDK4 (0.51) | CDK2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL3464981 | 0.76 | AURKA (0.43) | CDK2CDK1CDK4CCNB1CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| EP-2004615-A2 | QUINAZOLINES FOR PDK1 INHIBITION | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007117607-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007117607-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007117607-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117607-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | CDK2 29/4885CDK1 83/4885CDK4 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.